The estimated Net Worth of Vivek K Jayaraman is at least 3.57 百万$ dollars as of 12 March 2024. Mr. Jayaraman owns over 53,041 units of Cerus stock worth over 1,801,239$ and over the last 8 years he sold CERS stock worth over 458,303$. In addition, he makes 1,312,270$ as Chief Operating Officer、 Chief Commercial Officer at Cerus.
Vivek has made over 9 trades of the Cerus stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 53,041 units of CERS stock worth 107,143$ on 12 March 2024.
The largest trade he's ever made was exercising 112,900 units of Cerus stock on 12 March 2022 worth over 231,445$. On average, Vivek trades about 25,760 units every 79 days since 2017. As of 12 March 2024 he still owns at least 878,653 units of Cerus stock.
You can see the complete history of Mr. Jayaraman stock trades at the bottom of the page.
Vivek K. Jayaraman serves as Chief Operating Officer, Chief Commercial Officer of the Company. He previously served as our Chief Commercial Officer since August 2016. From October 2009 to February 2016, Mr. Jayaraman served as Vice President, Sales and Marketing of TriVascular Technologies, Inc., or TriVascular, where he oversaw TriVascular’s commercial expansion as the company grew from a preclinical, venture-backed startup into a publicly traded, global medical device company. Mr. Jayaraman received his MBA from the Wharton School at the University of Pennsylvania and holds dual bachelor’s degrees from the University of Michigan.
As the Chief Operating Officer、 Chief Commercial Officer of Cerus, the total compensation of Vivek Jayaraman at Cerus is 1,312,270$. There are 1 executives at Cerus getting paid more, with William Greenman having the highest compensation of 3,270,180$.
Vivek Jayaraman is 45, he's been the Chief Operating Officer、 Chief Commercial Officer of Cerus since 2020. There are 13 older and no younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
Vivek's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: